Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: A phase I/II study

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  Zhao, Jian Dong ^a   Liu, Jin ^a   Ren, Zhi Gang ^a   Gu, Ke ^a   Zhou, Zhen Hua ^a   Li, Wen Tao ^a   Chen, Zhen ^a   Xu, Zhi Yong ^a   Liu, Lu Ming ^a   Jiang, Guo Liang ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; MITOMYCIN C; OXALIPLATIN; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CYTOLOGY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INTENSITY MODULATED RADIATION THERAPY; LIVER CELL CARCINOMA; LIVER DISEASE; MAINTENANCE THERAPY; MORNING DOSAGE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; LIVER TUMOR; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PHASE 3 CLINICAL TRIAL; RADIOTHERAPY;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; PYRIDINES; RADIOTHERAPY; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RESEARCH DESIGN;

EID: 77649228957     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-12     Document Type: Article

References (22)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699. 10.1056/NEJM199603143341104, 8594428.
3. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739. 10.1016/S0140-6736(02)08649-X, 12049862.
4. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171. 10.1053/jhep.2002.33156, 11981766.
5. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003, 37:429-442. 10.1053/jhep.2003.50047, 12540794.
6. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxi A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002, 224:47-54. 10.1148/radiol.2241011262, 12091661.
7. Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006, 106:1653-1663. 10.1002/cncr.21811, 16541431.
8. Liang SX, Zhu XD, Lu HJ, Pan CY, Li FX, Huang QF, Wang AY, Chen L, Fu XL, Jiang GL. Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer 2005, 103:2181-2188. 10.1002/cncr.21012, 15812834.
9. Cheng JC, Chuang VP, Cheng SH, Huang AT, Lin YM, Cheng TI, Yang PS, You DL, Jian JJ, Tsai SY, Sung JL, Horng CF. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2000, 47:435-442. 10.1016/S0360-3016(00)00462-4, 10802371.
10. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390. 10.1056/NEJMoa0708857, 18650514.
11. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34. 10.1016/S1470-2045(08)70285-7, 19095497.
12. Zhao JD, Xu ZY, Zhu J, Qiu JJ, Hu WG, Cheng LF, Zhang XJ, Jiang GL. Application of active breathing control in 3-dimensional conformal radiation therapy for hepatocellular carcinoma: The feasibility and benefit. Radiother Oncol 2008, 87:439-444. 10.1016/j.radonc.2007.12.006, 18334274.
13. Liang SX, Zhu XD, Xu ZY, Zhu J, Zhao JD, Lu HJ, Yang YL, Chen L, Wang AY, Fu XL, Jiang GL. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: The risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 2006, 65:426-434.
14. Makuch RW, Simon RM. Sample size considerations for non-randomized comparative studies. J Chron Dis 1980, 33:175-181. 10.1016/0021-9681(80)90017-X, 7354106.
15. Yu YQ, Xu DB, Zhou XD, Lu JZ, Tang ZY, Mack P. Experience with liver resection after hepatic arterial chemoembolization for hepatocellular carcinoma. Cancer 1993, 71:62-65. 10.1002/1097-0142(19930101)71:1<62::AID-CNCR2820710111>L3.0.CO;2-8, 8380123.
16. Sasaki Y, Imaoka S, Kasugai H, Fujita M, Kawamoto S, Ishiguro S, Kojima J, Ishikawa O, Ohigashi H, Furukawa H. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 1987, 60:1194-1203. 10.1002/1097-0142(19870915)60:6<1194::AID-CNCR2820600607>3.0.CO;2-T, 2441837.
17. Meng MB, Cui YL, Lu Y, She B, Chen Y, Guan YS, Zhang RM. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 2009, 92:184-194. 10.1016/j.radonc.2008.11.002, 19042048.
18. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002, 25:511-518. 10.1159/000068621, 12566895.
19. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 2002, 8:2255-2257. 10.2174/1381612023393026, 12369853.
20. Cheng JC, Chou CH, Kuo ML, Hsieh CY. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 2006, 25:7009-7018. 10.1038/sj.onc.1209706, 16732316.
21. Chung YL, Jian JJ, Cheng SH, Tsai SY, Chuang VP, Soong T, Lin YM, Horng CF. Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res 2006, 12:2706-2715. 10.1158/1078-0432.CCR-05-2721, 16675562.
22. Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, Cerniglia G, Rajendran RR, Gupta A, Rustgi AK, Diehl JA, Smith CD, Flaherty KT, El-Deiry WS. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 2007, 67:9443-9454. 10.1158/0008-5472.CAN-07-1473, 17909054.